Non-small-cell Lung Cancer Clinical Trial
Official title:
Combination of Gefitinib With Chemotherapy or Anti-angiogenesis as 1st Line Treatment in Advanced NSCLC Patients Detected With Bim Deletion or Low EGFR Activating Mutation Abundance
This is a single arm phase II clinical trial, which aims to evaluate the effectiveness of combination of gefitinib and doublet chemotherapy or antiangiogenesis in advanced non-small cell lung cancer patients with EGFR activating mutation, accompanied with Bim deletion or low activating EGFR mutation abundance.
BIM deletion polymorphism and low EGFR mutation abundance were poor clinical response
markers to EGFR-TKIs in NSCLC patients who had EGFR mutations.This is a phase II clinical
trial to investigate the efficacy of combination treatment for patients harboring risk
factors.
Advanced EGFR mutated NSCLC Patients with Bim deletion or EGFR low mutation abundance were
randomizely divided into three treatment groups:
A:Gefitinib 250mg Qd B:Gefitinib 250mg Qd combined with doublet chemotherapy: Pemetrexed
(500mg/m²day 1 intravenously) plus carboplatin (AUC=5,day 1,intravenously) every 21 days,
Gemcitabine (1000 mg/m² days 1, day8, intravenously) plus carboplatin (AUC=5,day
1,intravenously) every 21 days C:Gefitinib 250mg Qd combined with bevacizumab 7.5mg/kg
intravenously per 21 days.
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02495233 -
A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)
|
Phase 1/Phase 2 | |
Withdrawn |
NCT02672358 -
Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC
|
Phase 2 | |
Recruiting |
NCT05815472 -
Advanced Patient Monitoring and A.I. Supported Outcomes Assessment in Lung Cancer Using Internet of Things Technologies (A.I. - APALITT)
|
N/A | |
Not yet recruiting |
NCT05900219 -
Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical Study
|
Phase 2 | |
Not yet recruiting |
NCT04560244 -
A Trial of SHR1701 Combined With Radiotherapy for Metastatic Non-small Cell Lung Cancer Failure After First-line Treatment
|
Phase 2 | |
Not yet recruiting |
NCT02907606 -
Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective Study
|
N/A | |
Completed |
NCT01924416 -
Lung Cancer Information Study (LCIS-R01)
|
N/A | |
Completed |
NCT01136083 -
Effect of Exercise Training on Angiogenesis and Cachexia in Lung Cancer Patients
|
N/A | |
Completed |
NCT00831454 -
Identification of EGFR-TKIs Sensitivity or Resistance Markers in NSCLC May Help in Optimal Patient Selection
|
N/A | |
Completed |
NCT00363766 -
Study of LY573636-Sodium in Patients With Metastatic Non-Small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT00913705 -
Neoadjuvant or Adjuvant Chemotherapy in Patients With Operable Non-small-cell Lung Cancer
|
Phase 3 | |
Completed |
NCT01124864 -
A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy.
|
Phase 2 | |
Completed |
NCT01383135 -
Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2
|
Early Phase 1 | |
Completed |
NCT00049998 -
Oral Topotecan Versus Intravenous Docetaxel In Pretreated, Advanced Non-Small Cell Lung Cancer
|
Phase 3 | |
Terminated |
NCT05061537 -
Study of PF-07263689 in Participants With Selected Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT03320044 -
Early Diagnosis of Small Pulmonary Nodules by Multi-omics Sequencing
|
||
Recruiting |
NCT04895930 -
Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC
|
Phase 2 | |
Recruiting |
NCT03267654 -
Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance
|
Phase 2 | |
Recruiting |
NCT04401059 -
Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC:Prospective Study
|
Phase 4 | |
Not yet recruiting |
NCT02938546 -
18F-FDG Metabolism Imaging Monitoring Non-small Cell Lung Cancer Curative Effect of Chemotherapy Multicenter Clinical Study
|
Phase 3 |